Asset Details
Do you wish to reserve the book?
Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities
Do you wish to request the book?
Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities
2022
Overview
The molecular events and transcriptional plasticity driving brain metastasis in clinically relevant breast tumor subtypes has not been determined. Here we comprehensively dissect genomic, transcriptomic and clinical data in patient-matched longitudinal tumor samples, and unravel distinct transcriptional programs enriched in brain metastasis. We report on subtype specific hub genes and functional processes, central to disease-affected networks in brain metastasis. Importantly, in luminal brain metastases we identify homologous recombination deficiency operative in transcriptomic and genomic data with recurrent breast mutational signatures A, F and K, associated with mismatch repair defects,
TP53
mutations and homologous recombination deficiency (HRD) respectively. Utilizing PARP inhibition in patient-derived brain metastatic tumor explants we functionally validate HRD as a key vulnerability. Here, we demonstrate a functionally relevant HRD evident at genomic and transcriptomic levels pointing to genomic instability in breast cancer brain metastasis which is of potential translational significance.
The molecular landscape of breast cancer brain metastases (BCBM) is still understudied, especially for different breast cancer subtypes. Here, the authors characterise subtype-specific BCBMs using genomics and transcriptomics and identify homologous recombination deficiency as a key therapeutic vulnerability.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 38/39
/ 45/23
/ 49/23
/ 49/91
/ Adult
/ Brain
/ Brain Neoplasms - metabolism
/ Breast
/ Breast Neoplasms - metabolism
/ Explants
/ Female
/ Genomics
/ Homology
/ Humanities and Social Sciences
/ Humans
/ Mutation
/ Patients
/ Poly(ADP-ribose) Polymerase Inhibitors - pharmacology
/ Science
/ Tumors
